Since YM-2A directly activates antigen-presenting cells in vitro and increased the numbers of splenic DCs and T cells in vivo, we next assessed whether oral administration of YM-2A can induce IFN-γ expression by CD4+ and CD8+ T cells in tumor-bearing mice. The gene discussed is CD4; the disease is neoplasm.